A meta-analysis of randomized control trials comparing antitumor necrosis factor (TNF) therapy with placebo found that anti-TNF therapy significantly increases the risk of opportunistic infections in IBD patients [13, 14]. The gene discussed is TNF; the disease is inflammatory bowel disease.